Combination of QLS31905, QL2107 and Chemotherapy as First-line Therapy in CLDN18.2-positive Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Clinical trial NCT06942767 · NOT_YET_RECRUITING

Trial details

NCT number: NCT06942767
Sponsor: Qilu Pharmaceutical Co., Ltd.
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Gastric Adenocarcinoma Gastroesophageal Junction Adenocarcinoma

Start date: 2025-06-01
Primary completion: 2026-12-01
Enrollment: 100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.